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Abstract
Anthrax toxin, which is released from the Gram-positive bacterium Bacillus anthracis, is composed of three proteins:
protective antigen (PA), lethal factor (LF), and edema factor (EF). PA binds a receptor on the surface of the target cell and
further assembles into a homo-heptameric pore through which EF and LF translocate into the cytosol. Two distinct cellular
receptors for anthrax toxin, TEM8/ANTXR1 and CMG2/ANTXR2, have been identified, and it is known that their extracellular
domains bind PA with low and high affinities, respectively. Here, we report the crystal structure of the TEM8 extracellular
vWA domain at 1.7 A ˚ resolution. The overall structure has a typical integrin fold and is similar to that of the previously
published CMG2 structure. In addition, using structure-based mutagenesis, we demonstrate that the putative interface
region of TEM8 with PA (consisting of residues 56, 57, and 154–160) is responsible for the PA-binding affinity differences
between the two receptors. In particular, Leu56 was shown to be a key factor for the lower affinity of TEM8 towards PA
compared with CMG2. Because of its high affinity for PA and low expression in normal tissues, an isolated extracellular vWA
domain of the L56A TEM8 variant may serve as a potent antitoxin and a potential therapeutic treatment for anthrax
infection. Moreover, as TEM8 is often over-expressed in tumor cells, our TEM8 crystal structure may provide new insights
into how to design PA mutants that preferentially target tumor cells.
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Introduction
Anthrax is a lethal infectious disease caused by Bacillus anthracis,
a Gram-positive, spore-forming, rod-shaped bacterium that
secretes three toxin proteins: lethal factor (LF), edema factor
(EF), and protective antigen (PA) [1]. They are collectively called
anthrax toxin, and PA is responsible for interaction with receptors
on target cell surfaces [2].
Anthrax toxin enters target cells through a multi-step mecha-
nism. First, full-length PA (PA83, 83 kDa) binds cell surface
receptors and is cleaved by cellular furin-like enzymes [3,4]. The
remaining activated PA protein (PA63, 63 kDa) then oligomerizes
into a heptameric structure known as a prepore and interacts with
EF and/or LF, which are located between two adjacent PA
monomers [5,6,7,8]. The entire receptor–toxin complex is then
transported into low-pH endosomes via endocytosis [9]. Pore
formation across the endosomal membrane is triggered by
increasing acidity, which induces a pivotal conformational
rearrangement of the prepore assembly [2,10]. Thus, understand-
ing the PA-receptor interaction is critical for anthrax toxicity
prevention and other potential therapeutic applications.
By using a genetic approach, two PA cell surface receptors have
been identified: TEM8/ANTXR1 (tumor endothelial marker 8/
anthrax toxin receptor 1) and CMG2/ANTXR2 (capillary
morphogenesis protein 2/anthrax toxin receptor 2) [11,12].
CMG2 is the major receptor mediating lethality of anthrax toxin
in vivo [13]. TEM8 and CMG2 are type I transmembrane proteins
with three domains: an N-terminal, extracellular von Willebrand
factor type A domain (vWA domain), a single transmembrane
spanning domain, and a C-terminal cytosolic domain [11,12].
Their vWA domains share approximately 55% sequence identity.
Compared to the wide distribution of CMG2 in normal adult
tissues (e.g., lung, brain, kidney, and muscle), TEM8 is only weakly
detected in these tissues but abundant in tumor endothelial cells
and the vasculature of developing embryos [11,14,15]. This is one
of the reasons that CMG2 plays a more important role in anthrax
toxin transportation into cells than TEM8. The physiological
ligands of these two receptors, as well as their cellular functions,
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between these proteins allow the specific targeting of tumor cells
using the PA–receptor system.
Moreover, the PA-binding affinities of TEM8 and CMG2 are
strikingly different. CMG2 was reported to have approximately
1000-fold higher affinity for PA (Kd=170 and 780 pM for the
Mg
2+- and Ca
2+-bound complexes, respectively) than TEM8
(Kd=1.1 mM and 130 nM for the Mg
2+- and Ca
2+-bound
complexes, respectively) [16,17], the latter of which is about the
average level of integrin-ligand interaction [18]. Structural details
and mutation analysis of TEM8 will be necessary to explain the
huge difference in PA-binding affinity between TEM8 and
CMG2. Meanwhile, PA mutants that can selectively bind with
either TEM8 or CMG2 have been designed and tested, and they
are potential therapeutic agents for cancer treatment [19].
The MIDAS (metal ion-dependent adhesion site) motif in vWA
domains can exist in either of two conformations, much like the
integrin I domain: closed (low-affinity ligand binding state) and
open (high-affinity ligand binding state) [20]. In a previously
reported CMG2 structure, the metal ion-coordinating residues of
CMG2 adopted the open state with an acetate molecule as a
mimic ligand, and such an open form is believed to attribute to the
higher affinity of CMG2 towards PA [10,14,21,22]. Results from
mutational analysis suggested that TEM8 also adopts an open
conformation [23]. However, such a notion remains to be proved
experimentally.
The pH threshold for conversion of the PA prepore to the pore
and toxin translocation is also receptor-specific. The pH required
for CMG2-associated toxin pore formation (pH 5.0) is lower than
that of TEM8 (pH 6.0) [24]. Interestingly, the CMG2 Y119H
variant with a mutation in the ligand-binding pocket further
lowers the pH threshold [25,26], and CMG2-mediated intoxica-
tion is blocked by ammonium chloride (NH4Cl) treatment, which
raises the endosomal pH [24]. A model of CMG2-associated toxin
prepore-to-pore conversion has been proposed in which the
receptor restrains the membrane insertion loop (b2–b3, residues
285–340) of PA domain 2 until protonation of PA and/or CMG2
residues loosen this interaction to allow PA domain 2 to form an
extended b-barrel pore. However, determining whether this model
is suitable for TEM8-mediated intoxication and which key TEM8
residues are responsible for the different pH thresholds requires
additional TEM8 structural information, particularly concerning
its vWA domain.
Here we report the high resolution structure of the TEM8 vWA
domain. We found that the vWA domain contains a chelated
Mg
2+ ion and a bound pseudo-ligand (i.e., an acetate ion from the
crystallization buffer) in its MIDAS site. Based on structural
analysis, we discuss a probable structural explanation for the
difference between TEM8- and CMG2-mediated toxin interaction
and pore formation. We also carried out a systematic mutational
analysis of TEM8 using cell protection assays, surface plasmon
resonance (SPR), and pH-dependent SDS-PAGE to verify our
hypothesis.
Results
Overall structure of the extracellular domain of TEM8
We obtained only one qualified crystal after screening more
than 200 crystals in two crystallization conditions. The crystal
belongs to the P1 space group and diffracted up to 1.7 A ˚
resolution. The crystal structure was solved using the molecular
replacement method from synchrotron data (PF, Japan). The
model was built from residues Ala38 to Cys220; Eight residues
(MSHHHHHH) of N-terminal affinity tag were not modeled due
to poor electron density and the following two residues (SM) linked
to the target protein can be determined in the electron density
map and refined as residue 36 and 37 in the final model. The
structure model was refined to a final R-factor of 0.194 and R-free
of 0.232 (Supplemental Data Table S1).
Our crystal structure contained six TEM8 vWA molecules
(labeled as A, B, C, D, E, and F) in the asymmetric unit (also unit
cell) (Figure 1). Three monomers were related by a non-
crystallographic three-fold symmetry to form a trimer, and two
of such trimers (A-B-C and D-E-F) formed a hexamer with an
overall ball-like shape through a two-fold axis perpendicular to the
three-fold axis (Figure 1A, 1B). The dimensions of the ball are
,82682666 A ˚. In this hexamer, the MIDAS ligand binding area
from each monomer was blocked, which would definitely interrupt
the interaction between TEM8 and PA (Supplemental Data
Figure S1). This indicates that such a hexamer is an inactive
oligomeric form. Moreover, TEM8 was determined to exist as a
monomer in solution by analytical ultracentrifuge (Supplemental
Figure 1. TEM8 vWA domain hexamer in the crystal cell. Protein molecules are shown in ribbon presentation. Six TEM8 vWA domain
molecules (labeled A–F) form two trimers, which further assemble into a ball shape in the asymmetric unit. Each TEM8 molecule is shaded with a
unique color. The dimensions of the ball are ,82682666 A ˚.
doi:10.1371/journal.pone.0011203.g001
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hexamer is most likely an artifact of crystal packing.
Consistent with their sequence homology, the structure of the
TEM8 extracellular domain is very similar to that of CMG2 and
the integrin A domain [21,27]. It adopts a classical a/b open sheet
fold that has also been called the dinucleotide-binding fold,
Rossmann fold, or doubly wound fold [21]. Five parallel b-strands
(i.e., b1, residues 42–50; b2, 77–85; b4, 73–79; b5, 173–179; and
b6, 196–199) and one short antiparallel b strand (b3, 89–96) form
a central b-sheet. The hydrophobic residues of the b-sheet form a
hydrophobic core on each side, surrounded by six amphipathic a-
helices (a1, 53–72; a2, 99–110; a3, 120–135; a4, 141–149; a5,
155–170; and a6, 200–217) (Figure 2A). It should be noted that
three acetate ions were found in each of the six TEM8 molecules
and were well defined in the electron density map. One of them
appeared to correspond to an analogous ion in the CMG2
structure, which acted as a mimic ligand of the side chain of D683
in PA and occupied the MIDAS coordination site (Figure 2B). The
existence of the other two acetate ions may be incidental to our
crystal form due to the 0.2 M ammonium acetate included in the
crystallization buffer.
An open conformation of the TEM8 vWA domain
The extracellular domain of TEM8 shares a common topology
with a wide variety of intracellular enzymes and cell adhesion
molecules. Not surprisingly, CMG2 is the most similar structure to
TEM8, according to the 3D structure similarity search engine
DALI [28]. Two crystal structures of CMG2 have been reported
(PDB ID 1SHU and 1SHT), and the structural superpositioning of
the TEM8 vWA domain with CMG2 yielded a root mean
square deviation (rmsd) of 1.2 A ˚ for 175 common Ca atoms in
CMG2-S38 (residues 38–218; 1SHU) and 1.6 A ˚ for 168 common
Ca atoms in CMG2-R40 (residues 40–217; 1SHT). The main
quaternary structure differences between TEM8 and CMG2
occurred in the a3–b4 loop and helix a6. First, the TEM8 a3–b4
loop moved 10 A ˚ compared with CMG2, and the sequence of the
a3–b4 loop varied between TEM8 and CMG2. Second, while the
N-termini of a6 in the two structures were located at the same
Figure 2. Overall structure of the TEM8 vWA domain and its open conformation. (A) TEM8 vWA domain structure (side view). Five parallel
b strands (b1, b2, b4, b5, and b6) and one short anti-parallel b-strand (b3) form a central sheet that is surrounded by six a-helices (a1–a6). This structure
contains a chelated Mg
2+ ion (light green sphere) in the MIDAS site, with a bound pseudo-ligand contributed by an acetate ion (ACT1, purple). Two
additional acetate ions (ACT2 and ACT3, purple) are also observed in the structure. (B) TEM8 MIDAS site (top view). Ser52 and Ser54 in helix a1 (blue)
and Thr118 in a3 (green) form direct bonds that coordinate the Mg
2+ ion, while Asp50 in a1 (blue) and Glu152 and Asp150 in the a4–b4 loop (yellow)
form water-mediated hydrogen-bonds to the metal ion. The rest of the MIDAS coordination site is occupied by a mimic ligand (i.e., the acetate ion,
ACT1, purple). (C) TEM8 vWA domain structure (colored clay) was superimposed onto the CMG2-S38 vWA domain structure (colored green, PDB ID
1SHU). The most distinct sites are highlighted by pink ovals. (D) The superposition (top view) between the TEM8 vWA domain structure (clay), domain
I structure of Integrin CR3 in the open conformation (purple, 1IDO) and CR3 in the closed conformation (blue, 1JLM). The TEM8 vWA structure is much
closer to the open conformation.
doi:10.1371/journal.pone.0011203.g002
Crystal Structure of TEM8
PLoS ONE | www.plosone.org 3 June 2010 | Volume 5 | Issue 6 | e11203position, this conserved helix extended in different directions
(Figure 2C).
The TEM8 vWA domain structure also showed high similarity
with domain I of Integrin CR3 in the open conformation (2.1 A ˚
rmsd for 155 Ca atoms, PDB ID 1IDO [27]), CR3 in the closed
conformation (2.2 A ˚ for 156 Ca atoms, 1JLM [27]), Complement
Factor B (2.0 A ˚ for 162 Ca atoms, 1RRK [29]), complement C2
(2.1 A ˚ for 164 Ca atoms, 2ODP [30]), and Von Willebrand Factor
(2.5 A ˚ for 172 Ca atoms, 3GXB [31]), although they have low
sequence identity (18–26%). The integrin I domain has two
conformations, open and closed (Figure 2D), and the conversion
between these two conformations usually plays an important
biological function, representing the active and inactive states,
respectively [18,20,27]. In the open conformation, two serines and
a threonine residue tightly bind to the metal ion, and two water
molecules also bind directly to the metal ion, similar to that
described above for TEM8. In contrast, in the closed conforma-
tion, the metal ion shifts, and only the threonine can indirectly
contact the ion via a water molecule. Taken together, the TEM8
extracellular domain contained a conserved Mg
2+-coordinated
MIDAS motif that assumed an integrin-like open conformation.
The PA-binding interface of two receptors
Although TEM8 and CMG2 share high sequence identity, they
widely differ in binding affinities for PA and in pH thresholds for
forming SDS-resistant pores. The previously reported CMG2-PA
complex structure depicts extensive contact between CMG2 and
PA domains 2 and 4 [22]. CMG2 has a much larger contact
surface (,2000 A ˚ 2) than a typical a-integrin–ligand (,1300 A ˚ 2),
and it was believed that this larger surface is responsible for the
higher affinity of CMG2-PA binding [22,32]. However, we found
that the buried surface area between TEM8 and PA is very similar
to that of CMG2, as calculated by our TEM8-PA complex
structure model. According to the CMG2-PA complex and TEM8
structures, we superpose the TEM8 structure to CMG2-PA with
COOT and generate the TEM8-PA complex (Figure 3A). Thus, a
direct relationship between the buried surface area and affinity
does not hold. In order to investigate the structural basis of these
differences, we further compared the ligand binding sites of TEM8
and CMG2.
The Mg
2+ ion from the MIDAS site of CMG2 is directly
involved in PA-binding. Based on the sequence alignment of the
two receptors, there is a two residues width gap (from 135 to 136
of CMG2) between the TEM8 and CMG2 vWA domains.
Interestingly, most of those interface residues in CMG2 are not
conserved in the corresponding TEM8 sites (i.e., residues 56, 57,
87, 88, 113, 115, 117, 125, 154, 155, and 156 in TEM8). We can
divide these non-conserved residues into four regions in TEM8:
Part 1 (residues 56 and 57) is located in helix a1 (the
corresponding part in CMG2 interacts with domain 2 of PA);
Part 2 (residues 87 and 88) is located in the b2–b3 loop; Part 3
(residues 113–117, Tyr119, His121, Glu122, and Glu125) is
located in the a2–a3 loop; and Part 4 (residues 152–156 and
Tyr158) is located in the b3–b4 loop (Figure 3). Together, the
CMG2 Part 2–4 counterparts interact with domain 4 of PA. We
hypothesized that these non-conserved residues in the PA-binding
interface are responsible for the striking differences in PA binding
affinity, receptor-specific pH thresholds for pore formation, and
even translocation of the toxin.
Key residues resulting in the difference of binding affinity
between TEM8 and CMG2
We designed a number of TEM8 single point mutants (i.e.,
L56A, H57N, T87S, R88Q, D117E, H154D, E155G, D156L,
L157V, F158P, K51A, Y119H, Y119R, E122A, and E122H)
and multiple site mutants M1 (L56A and H57N) and M2
(L56A, H57N, H154D, D156L, L157V, and F158P). As stated
in the Materials and Methods, the C177A mutation was also
introduced in all of the above mutants in order to reduce
aggregation of the recombinant protein. Unfortunately, some
of the mutants were still insoluble in the E. coli expression
system and were excluded from further studies. We purified the
soluble mutants (i.e., L56A, H57N, T87S, R88Q, D117E,
H154D, L157V, F158P, K51A, Y119H, Y119R, E122A,
E122H, M1, and M2) and indirectly tested their PA binding
affinity using a J774 A.1 cell protection assay and the SPR
method.
The cell protection results showed that TEM8 Part 1 mutants
M1, M2, and especially L56A significantly increase the protective
ability (up to 7-fold in terms of IC50) compared to WT TEM8.
Their protective ability even exceeded the CMG2-R40 protein
(i.e., residues 40–217), in the absence of the only disulfide bond
between Cys39 and Cys218, and was one-third as strong as the
CMG2-S38 variant (i.e., residues 38–218) containing the disulfide
bond. In contrast, the H57N, R88Q, L157V, and F158P point
mutants had decreased protective ability. Further, the Part 4
H154D mutation resulted in a mild improvement of the PA-
binding ability, and Part 2 mutant T87S and Part 3 mutant
D117E had almost the same protective effect as WT TEM8.
These results indicated that TEM8 Parts 1 and 4 are likely to be
the main contributors to the PA affinity differences between
TEM8 and CMG2 (Figure 4).
Additionally, we used SPR to directly test whether the key
residues identified in the cell protection assay have different PA
binding abilities (Table 1). In particular, we tested the K51A,
L56A, T87S, R88Q, M1, and M2 mutants. The results showed a
clear correlation between cell protection ability and PA binding
ability. For instance, the L56A mutant had the highest PA-
binding affinity (KD of 4.4 nM) among the mutants tested, which
is close to the affinity of CMG2-R40 (2.4 nM). The M1 mutant
also showed a PA binding affinity (5.3 nM) similar to that of
CMG2. For comparison, the KD value of TEM8 WT was
29.8 nM. We should mention that this WT TEM8 KD we
measured was 4-fold lower than previous reported (130 nM), but
this difference is acceptable considering SPR system character-
istics [17] and we make sure this result was from very rigorous
repeatable experiments. Finally, the Part 2 T87S and R88Q
mutants had KD values of 49.7 nM and 167 nM, respectively,
indicating that these Part 2 mutants have 2- to 5.5-fold lower PA
binding affinity than the WT.
We also tested the effects of alanine substitution mutations of
some conserved residues (e.g., Lys51, Tyr119, and Glu122) in
TEM8. All of these mutants, especially K51A, reduced the
protective effect (KD decreased by 22-fold) (Figure 4, Table 1).
The conserved Lys51 residue plays an important role in
stabilizing the complex by making strong hydrogen bonds to
PA Glu654, as shown in the CMG2-PA complex [22].
Moreover, several groups have independently discovered that
CMG2 Tyr119 plays a key regulatory role in acid pH-dependent
pore formation [25,26]. Our cell protection data indicated that
TEM8 Tyr119 also plays an important role in protective ability
and PA binding affinity (Figure 4). According to our TEM8-PA
complex model, TEM8 Tyr119 inserts into a planar cleft
b e t w e e nd o m a i n s2a n d4o fP Aa n df o r m sah y d r o g e nb o n dw i t h
the backbone carbonyl oxygen of PA Ala341(Figure 5A). In
addition, TEM8 Glu122 forms a salt bridge with PA Arg344.
Thus, all of these conserved residues play important roles in PA
binding.
Crystal Structure of TEM8
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A possible explanation of mutation results based on the
PA-TEM8 complex model
In order to explain why the key residues of the two receptors
identified above play important roles in the difference of PA-
binding ability, we superimposed the TEM8 structure onto the
CMG2 molecule in the CMG2-PA complex structure, thus
creating a putative TEM8-PA complex model (Figure 3A). The
TEM8 L56A mutant stands out among all of the tested mutations.
It showed a sharp increase of protective ability and PA binding
affinity. This indicates that TEM8 Leu56 is an important
determinant of the difference between TEM8 and CMG2. This
may be explained by the structural observation that the side chain
of Leu56 clashes with a PA Tyr688 in our putative PA-TEM8
complex model (Figure 3E). In contrast, the corresponding CMG2
Ala56 has a short side chain and hence allows the CMG2 molecule
(residues 113 and 115) to contact a hydrophobic area of PA
(residues 687, 689, 646, and 652). In addition, according to the
data from the cell protection and SPR assays, both M1 and M2
mutants, which contain the L56A mutation, had a striking increase
in protective ability and PA binding affinity, further supporting the
important role of position 56 in determining PA-binding affinity.
Another readily noticeable 3D structural distinction can be
observed at residues 154–160 (HEDLFFY) in TEM8; the
corresponding residues in CMG2 are 152–158 (DGLVPSY)
(Figure 3B). In the PA-CMG2 complex structure (PDB ID
1T6B), Gly153, Leu154, and Val155 residues participate in
hydrophobic contacts with the side chains of PA residues Leu340
and Ala341. Therefore, substitution of Gly153 and Leu154 (in
CMG2) with Glu155 and Asp156 (in TEM8) would disturb this
hydrophobic interaction. In fact, an inspection of the TEM8-PA
Figure 3. TEM8-PA63 complex model and details of their interaction. (A) A model of PA63 and TEM8 vWA domain complex (PA63, cyan; TEM8
vWA domain, yellow; Mg
2+, green; and acetate ion, purple). The TEM8 vWA domain is superimposed onto the CMG2 vWA domain according to the
structure of the CMG2-PA complex (PDB ID 1T6B). (B–E) Comparison of the TEM8-PA63 binding surface and CMG2-PA63 binding surface. According to
our TEM8-PA63 complex model, there are four TEM8 regions anticipated to interact with PA63. Here, we show detailed structural differences between
the TEM8-PA63 binding surface and the CMG2-PA63 binding surface (TEM8, yellow; CMG2, purple; and PA63, cyan). The molecular surface of PA (cyan,
semi transparent) is also included. (B) Part 4 (residues 153–158), located in the b3–b4 loop interacts, with Leu340 and Ala341 in domain 4 of PA63.( C)
Part 3 (residues 113 and 115), located in the a2–a3 loop, interacts with a hydrophobic cleft comprised of Leu687, Ile689, Ile646, Phe678, and Ile656 of
PA63. The picture is reverse with box in A (D) Part 2 (residues 87 and 88), located in the b2–b3 loop, interacts with Asp657, Arg658, Asp714, and
Thr715 of PA63.( E) Part 1 (residues 56 and 57), located in helix a1, interacts with Tyr688 in domain 2 of PA63.
doi:10.1371/journal.pone.0011203.g003
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change of the main chain (a 3 A ˚ shift away from PA) (Figure 3B),
which would result in a loss of both the hydrophobic and Van der
Waals interactions. Previously, Young, Collier, and coworkers
identified that CMG2 G153 and L154 are key residues related to
the difference in PA binding ability and pH threshold [26]. It was
also hypothesized that mutations of Glu155 and Asp156 in TEM8
Part 4 would significantly affect PA binding affinity because there
is a significant position shift in the host loop between TEM8 and
CMG2. Unfortunately, the TEM8 D156L mutant (a substitution
to the corresponding CMG2 residue) was not expressed in a
soluble form in E. coli. We suspect that mutations in this loop may
have negative effects on overall stability. Furthermore, TEM8
Leu157 is located at a position similar to CMG2 Val155
(Figure 3B) but appears to have a more extensive interaction with
a PA hydrophobic surface. Consistent with this observation,
TEM8 L157V showed a lower PA binding (Figure 4). In our
TEM8 crystal structure, Phe158 is inserted into the hydrophobic
Figure 4. Inhibition ability of receptor variants (vWA domain) for protecting J774A-1 cells from PA intoxication. The survival rate is
calculated using the equation:
Survival rate~
ODsample{ODcontrol2
ODcontrol1{ODcontrol2
 100%
Control 1 is cells treated without either PA or receptors (mutants) and control 2 is cells treated with PA but without receptors. (A) The protective
ability (IC50) of TEM8 variants that replace the original residue with Ala or contrary charged residue at the conserved sites in the binding interface
between TEM8 and CMG2. (B) The protective ability (IC50) of TEM8 variants that replace the original residue with the corresponding residue in CMG2
at the non-conserved sites. Data points and error bar represent the mean 6 SEM values for three independent experiments in (A) and (B). (C) Survive
curves show the negative Log value of the IC50 by TEM8 variants/receptors, based on results showed by (A). In the same way, (D) is the corresponding
curves of (B). Data points and error bar represent the mean 6 SEM values for one representative experiment with duplicates in (C) and (D).
doi:10.1371/journal.pone.0011203.g004
Crystal Structure of TEM8
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a4 and a5 helices (Figure 3B). However, this change did not
obviously affect the binding ability (Figure 4B).
The other two parts of the receptor interface with PA, Part 2
(87–88) and especially Part 3 (113–122), bury a large amount of
surface area upon PA binding. The a2–a3 loop of TEM8 forms a
hydrophobic ridge that inserts into a groove formed by a b-
sandwich of the immunoglobulin-like fold of PA domain 4. Non-
intuitively, some of the TEM8 single mutations in Part 2 and Part
3 showed no significant effect on protective ability and PA binding.
Regardless, previous research also showed that the CMG2 S113L
and V115G mutants (equivalent to positions 113 and 115 in
TEM8) cause no change in protective ability [33]. Hence, we
sought to find some structural explanation for this structural
tolerance (Figure 3C, 3D). For example, in the TEM8 structure
Thr87 is hydrogen-bonded to the PA Ile656 backbone, and this
interaction is unperturbed in our T87S mutation. In contrast, the
R88Q mutant indeed reduced the protective ability (Figure 4 and
Table 1). The terminal amino nitrogen group, NH1, of the Arg88
side chain forms a strong hydrogen bond with PA Ser717, and the
other amino nitrogen group, NH2, of the Arg88 side chain forms a
salt bridge with PA Asp715. In the mutant, these two bonds were
replaced by a single hydrogen bond between Gln88 and PA
Thr716. This structural change weakens the interaction network
and causes a decrease in binding affinity. Therefore, TEM8 Parts
2 and 3 are likely to be essential in PA-binding, similar to the
equivalent parts in CMG2.
The relationship between binding affinity and the pH
threshold of pore formation
Another characteristic difference between TEM8 and CMG2 is
that the pH threshold for conversion of a PA prepore to pore is
altered by one full pH unit (TEM8, pH 6.0 in vivo and pH 6.8–7.1
in vitro; and CMG2, pH 5.0 in vivo and pH 5.7–5.8 in vitro) [24,26].
In our in vitro system, when PA was bound to TEM8, formation of
the SDS-PAGE resistant oligomer occurred at pH 6.8, and when
bound to CMG2, its formation occurred at pH 5.6. In a previous
report, Gly153 and Leu154, which contact PA domain 2, and
Table 1. The PA-binding kinetic ratio of CMG2
R40, TEM8 and its mutants based on SPR data.
Mutants ka (M
21s
21)k d (s
21)K D (M
a) replicates
TEM8 5.46E+0361.56E+03 1.40E20465.76E205 2.98E20868.88E209 4
CMG2
R40 4.53E+0463.42E+04 1.05E20467.67E205 2.43E20961.40E210 2
K51A 9.36E+0162.14E+01 5.27E20365.20E204 5.81E20567.80E206 2
L56A 1.49E+0462.12E+02 6.60E20569.19E206 4.44E20965.37E210 2
T87S 6.11E+0364.09E+03 2.59E20461.44E204 4.97E20867.30E209 2
R88Q 3.73E+0363.50E+02 6.21E20468.00E206 1.67E20764.00E209 2
M1 8.66E+0361.95E+03 4.46E20566.9E206 5.25E20963.75E210 2
M2 4.83E+0363.65E+02 5.79E20565.55E206 1.20E20862.50E210 2
aThe equilibrium dissociation constant was calculated from kinetic measurements of the association and dissociation rate constants according to KD=k d/ka.
bTEM8: TEM8 residues 38–220 with a C177A mutation as mentioned in materials and methods; CMG2
R40: CMG2 residues 40–217; M1 contains L56A and H57N mutations;
M2 contains L56A, H57N, H154D, E155G, D156L, L157V, and F158P mutations.
doi:10.1371/journal.pone.0011203.t001
Figure 5. Comparison of PA-CMG2 and PA M662R/R659S-CMG2. (A) PA-CMG2 complex (light blue, PDB ID 1T6B). The TEM8 vWA domain,
colored yellow, is superimposed onto the CMG2 vWA domain of the complex. (B) Model of the PA mutant (M662R/R659S) complexed with CMG2,
according to the structure of the PA-CMG2 complex. The TEM8 vWA domain was superimposed onto the CMG2 vWA domain. The mutated residue is
colored grey.
doi:10.1371/journal.pone.0011203.g005
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Arg88 in TEM8), are major determinants of the lower pH
threshold requirement associated with CMG2 [26]. Correspond-
ingly, Six TEM8 mutants (i.e., K51A, L56A, R88Q, H154D, M1,
and M2) were analyzed. M2 (154–158) showed a striking change
in the pH threshold of pore formation, with a value as
approaching to that of CMG2. Meanwhile, all single point
mutations did not cause a significant change in the pH threshold of
pore formation (Figure 6). We sought to determine whether there
was a correlative relationship between the binding affinity and pH
thresholds of pore formation in the two receptors. Interestingly,
the K51A, L56A, and M1 mutants that significantly altered the
binding affinity did not cause a significant change in the pH
threshold of pore formation. Thus, our data do not support a
simple, linear correlation between binding affinity and the pH
threshold of pore formation in the relationship between TEM8
and PA.
TEM8 L56A can be considered an anti-toxin drug
candidate
It was reported that soluble CMG2 and TEM8 extracellular
domains are antitoxins that can block intoxication of CHO-K1
cells by PA and LF [11,12,17]. Recently, a neutralizing
monoclonal antibody against the PA of B. anthracis was developed,
which can directly interact with the toxin and inactivate it [34,35].
However, some B. anthracis strains can express functional but
antigenically altered forms of PA, and such strains may elude
treatment with such anti-PA antibodies. Thus, soluble receptor
decoys are important in assisting antibody-based therapies [17].
However, the soluble WT TEM8 vWA domain is not as effective
as its counterpart from CMG2 due to the lower PA-TEM8
binding affinity. Indeed, to protect cultured CHO-K1 cells against
intoxication by 50% with soluble receptors, 200-fold more TEM8
is needed than CMG2 [17]. In the current study, the TEM8 L56A
mutant was tested for its ability to block intoxication and was
found to be very similar to CMG2. The IC50 of this TEM8 variant
was estimated to be 21.9 nM, whereas the IC50 of WT TEM8 was
143.2 nM. For comparison, the IC50 of soluble CMG2 with and
without the Cys39–Cys219 disulfide bond were estimated to be
6.1 nM and 40.6 nM, respectively (Figure 4). Considering the low
expression of TEM8 in normal tissues, the TEM8 L56A mutant
may incur less potential side-effects compared to the widely
expressed CMG2, thus it may become a safer and more promising
antitoxin than soluble CMG2.
A possible mechanism of selective interaction between
modified PA and receptors
TEM8 is difficult to detect in normal tissues but abundant in
tumor cells. This presents a possibility of targeting drugs to tumor
cells using a PA-TEM8-based system. Leppla and coworkers used
phage display to select PA variants that preferentially bind to
TEM8 over CMG2, in order to target tumor cells with modified
anthrax toxin PA [19]. One of their candidates, the PA R659S/
M662R protein, binds 10-fold more tightly to TEM8 than CMG2.
A structural explanation can be deduced from a comparison of our
PA-TEM8 model with the PA-CMG2 complex structure [21].
First, relative to WT PA, the M662R mutant may form two extra
salt bridges with TEM8 (Figure 5B): one with Tyr119 (Tyr119 in
CMG2) and the other with Asp117 (Glu117 in CMG2). However,
the latter one does not appear at the PA-CMG2 interface
(Figure 5B), thus giving TEM8 some extra binding advantage over
CMG2. Second, in PA, the R659S mutation eliminates an intra-
molecular hydrogen-bond with the Leu340 backbone. We
speculate that such a mutation may enhance PA–receptor binding
by giving the Leu340-residing loop more flexibility. Considering
some residues in TEM8, such as Y119, E122 and L340, may not
adopt the same configuration in the complex as shown the in free
TEM8 crystal structure, so the above explanation may not reflect
the real conformation change. However, this case still hints how
the crystal structure of the TEM8 vWA domain serves as a
structural model to lend support to manipulations of the TEM8-
PA interaction and hence sheds light on potential antitumor
therapies.
In this work, we determined the crystal structure of the TEM8
vWA domain at 1.7 A ˚ resolution. The structure aids our
understanding of how PA mediates anthrax toxin translocation
into cells and sheds light on functional differences between the two
anthrax receptors. The overall structure of TEM8 is quite similar
to the previously reported CMG2 structure; yet there are
numerous detailed structural differences. Among the four
sequence regions that interact with PA in our putative TEM8-
PA complex model, TEM8 Parts 1 and 4 in the PA binding
interface were the main determinants for the large difference of PA
binding affinity. Part 1 (residues 55 and 56) and Part 4 (residues
153 and 154) significantly affected binding affinity and partially
influenced the pH threshold of pore formation. Moreover, we
found that the TEM8 L56A mutant strikingly increased the PA
binding affinity and hence can be used as a good decoy antitoxin.
In addition, based on our PA-TEM8 complex model, we analyzed
why the PA M662R/R659S mutant preferentially binds to TEM8
over CMG2, highlighting the possibility to create more effective
PA mutants based on our TEM8 structure.
Materials and Methods
Protein expression and purification
The cDNA sequence encoding the human TEM8 (GenBank ID
NP_115584.1) vWA domain (residues 38–220) was cloned into the
pHAT2 vector (EMBL) for expression as an N-terminal His-tag
fusion protein (The N-terminal affinity tag residues were
MSHHHHHHSM). In order to reduce aggregation of the
recombinant protein, we also introduced a C177A mutation in
the wild type (WT) TEM8 clone and subsequent mutant variants.
Recombinant C177A protein was expressed in the soluble fraction
in Escherichia coli strain BL21 (DE3) with a higher yield (more than
two-fold) and was less susceptible to precipitation than the WT
Figure 6. pH threshold of pore formation of TEM8 variants.
Formation of SDS-PAGE resistant oligomers is assayed at different pH
values in solution with the vWA domain of the WT receptors and TEM8
mutants. Experiments have been repeated at least twice and the results
were identical.
doi:10.1371/journal.pone.0011203.g006
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later in this study revealed that residue 177 was buried in a
hydrophobic core and isolated, similar to the corresponding
CMG2 structure. Thus, it is reasonable to deduce that this single
point mutation would not induce a large scale conformational
change at the MIDAS site and related interface with PA.
Hereafter, for simplicity, we refer to the TEM8 C177A single
point mutant as WT.
Crystallization
The TEM8 extracellular vWA domain crystals were grown by
the hanging-drop vapor diffusion method at 22uC by mixing 1 ml
of 5 mg/ml protein solution with 1 ml of reservoir solution (0.1 M
sodium citrate trihydrate (pH 5.6), 0.2 M ammonium acetate, and
20% (w/v) polyethylene glycol 4000). We also directly added
0.1 M hexammine cobalt (III) chloride (Hampton Research) as an
additive to the hanging drop (10% volume ratio) during
optimization. The shape of the final crystals was laminary, and
the crystals attained their maximum size (0.160.160.02 mm) after
10 d.
Data collection and structure determination
Prior to data collection, the crystals were plunged into liquid
nitrogen and transported to the cold nitrogen stream of beamline
17A at the Photon Factory synchrotron facility (Tsukuba, Japan).
20% (w/v) PEG 4000 in the reservoir solution was very suitable
cryoprotectant for this crystal. Diffraction data were processed
with the HKL2000 program at 1.7 A ˚ resolution, and the crystal
belongs to space group P1, with unit cell dimensions a=65.9 A ˚,
b=66.1 A ˚, c=74.4 A ˚, a=63.7u, b=88.2u, and c=59.9u. Our
attempt to process the data in higher symmetry space groups failed
because of significantly worse Rmerge values. The data collection
statistics in the P1 crystal form are shown in Supplemental Data
Table S1. Each asymmetric unit in the crystal contains six
molecules of the TEM8 extracellular vWA domain. The
diffraction phases were determined by the molecular replacement
method, using the program PHASER [36] and the CMG2 vWA
domain structure (PDB ID 1SHU) as the initial model. The TEM8
model was further built manually with COOT [37] and refined
using REFMAC [38] from the CCP4 suite [39]. The TEM8
structure was refined to a final Rfree=23.2% and Rwork=19.4%.
The stereochemistry was of excellent quality, as validated by the
program PROCHECK [40]. Final refinement statistics are also
summarized in Table S1.
Protection of mammalian cells from PA intoxication
Murine monocyte–macrophage cells J774A.1 [American Type
Culture Collection, Manassas, VA] were plated at a density of
30,000 cells/well in 96-well plates and cultured for 24 h before
toxin treatment. A dilution series of TEM8 and its mutants,
combined with PA proteins (100 ng/ml) and LF (100 ng/ml), was
applied to the cells to a final volume of 100 ml/well. Cell viability
was assayed 4 h after treatment by replacing the medium with
100 ml solution containing 1 mg/ml MTT (3-[4,5- dimethylthiazol
-2-yl]-2,5-diphenyltetrazolium bromide), which was removed after
a 1 h incubation at 37uC. The blue pigment (i.e., oxidized MTT)
produced by viable cells was dissolved in 50 ml/well of 0.5% (w/v)
SDS and 25 mM HCl in 90% (v/v) isopropanol, and the plates
were vortexed. The A570 of oxidized MTT was measured using a
Microplate Reader Model 550 (Bio-Rad Inc, Foster), and the data
were analyzed with Prism software (GraphPad Software Inc, San
Diego) as the percentage viability of control wells containing LF
without PA. IC50 values were determined by nonlinear regression
sigmoidal dose-response analysis with variable slopes. Each assay
was performed in triplicate, and the assay was repeated at least
four times independently. Data from representative assays are
shown in Figure 4.
pH-dependent conversion of the prepore to an SDS-
resistant state
Receptor protein (15 mg) was added to PA63 heptamer prepore
(25 mg). MgCl2 was added to the reaction to a final concentration
of 1 mM, and the mixture was left at room temperature for
20 min to allow complete binding. Reactions were divided into
aliquots and incubated for 1 h with equal volumes of the following
buffers: 1 M MES (pH 6.0), 1 M MES (pH 6.2), 1 M MES
(pH 6.4), 1 M MES (pH 6.6), 1 M MES (pH 6.8), or 1 M HEPES
(pH 7.0). Samples were then mixed with 2% SDS loading buffer of
for 20 min. Their molecular weights were analyzed on a 3–12%
Tris-Glycine gel in SDS running buffer. The protein complex
bands were visualized by Coomassie Blue staining and digitalized
with the computer program Bandscan (Glyko Inc).
SPR assays
Surface plasmon resonance, to measure the binding between PA
and receptor variants, was performed using the Biacore 2000
system. Monomeric PA83 was covalently linked to the carboxyl-
ated dextran matrix. It was diluted to 4 mM in sodium acetate
buffer (pH 5.0), injected onto the activated surface at a flow rate of
5 ml/min for 65 min, and then blocked with ethanolamine. The
vWA domains of the receptor variants (i.e., the analytes) were
diluted to various concentrations (50–800 nM) in HEPES buffered
saline (HBS, i.e. 10 mM HEPES (pH 7.4), 150 mM NaCl, and
0.005% (v/v) TWEEN-20) with additional 1 mM Mg2+, and
serial injections were made at 20 ml/min at 25uC. After sample
analysis, CM5 baselines were regenerated with 10 mM/L glycine
HCl (pH 2.0) for 15 s and borate buffer (10 mM sodium
tetraborate (pH 8.5) and 1 M NaCl) for 15 s.
Supporting Information
Figure S1 The MIDAS site of one TEM8 vWA domain
molecule was blocked by the adjacent molecule in the crystal cell.
Protein molecules are shown in ribbon presentation. Only two
adjacent TEM8 vWA domain molecules are shown and labeled as
A, B in the crystal. The MIDAS site of A molecule (purple) is
highlighted with a pink background. The MIDAS site of molecule
A is blocked by molecule B (red) from above by steric hindrance.
PA cannot interact with A’s MIDAS site.
Found at: doi:10.1371/journal.pone.0011203.s001 (2.90 MB TIF)
Figure S2 Sedimentation Velocity Data for TEM8. Curve
represents a sedimentation velocity run for TEM8. This curve has
only one peak (19.5 kD) that is close to the TEM8 vWA domain
monomer’s theoretic molecular weight, which demonstrates the
TEM8 vWA domain molecule to exist as monomer in the solution.
Sedimentation velocity (SV) experiment was conducted with an
Optima XL-L analytical ultracentrifuge (Beckman-Coulter Instru-
ments). An An60Ti rotor and standard six-sector equilibrium
centerpieces were used. Freshly prepared TEM8 was further
purified and buffer-exchanged into sedimentation buffer (150 mM
NaCl and 25 mM Tris-HCl, pH 8.0) using a gel filtration column.
c(M) distribution for TEM8 (1 mg/ml, Black line) obtained from
sedimentation velocity experiments, at 20uC and a speed of
40,000 rpm. Absorbance scans were carried out at a wavelength of
280 nm, and 98 scans were collected at 2 min intervals.
Found at: doi:10.1371/journal.pone.0011203.s002 (0.75 MB TIF)
Table S1 Data collection and refinement statistics.
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